Bausch & Lomb Inc. is nearing a deal to sell itself to drug maker Valeant Pharmaceuticals International Inc. for about $9 billion, according to people familiar with the matter�a surprise move that highlights a resurgence in private-equity deal making after years ...
Valeant Pharmaceuticals eyes Bausch & Lomb
Globe and Mail
Warburg Would Reap Threefold Return in Bausch Transaction
Related articles »